Core Viewpoint - Da Cheng Biochemical Technology (00809) expects a significant decline in net income for the fiscal year ending December 31, 2025, projecting between HKD 100 million and HKD 300 million, compared to approximately HKD 746 million for the fiscal year ending December 31, 2024 [1] Financial Performance - The company anticipates revenue and gross profit to increase by approximately 13.9% and 2.8%, respectively, from about HKD 2.001 billion and HKD 191 million in the previous year to approximately HKD 2.279 billion and HKD 196 million in the current year [1] - However, the gross profit margin is expected to decline from 9.5% in the previous year to 8.6% in the current year [1] Factors Affecting Performance - The anticipated decline in gross profit margin and net income is primarily attributed to rising domestic corn prices starting mid-2025, which will increase operational costs for the company [1] - Additionally, the European Union's anti-dumping investigation into mainland China's lysine has led to an oversupply of lysine products in the domestic market, negatively impacting the company's gross profit margin [1] - The company will also not recognize a one-time gain of approximately HKD 1.962 billion following the completion of the sale of eight subsidiaries on December 30, 2024 [1]
大成生化科技(00809)发盈警 预期2025年净收益约1亿港元至3亿港元